San Jose, California (PRWEB) October 15, 2012
Follow us on LinkedIn Post-surgical adhesion formation is one of the most common complications associated with surgery. Adhesions are generally referred as undesirable side effects of human bodys wound healing process. These adhesions are common in abdominal surgeries, cardiovascular procedures and orthopedic surgeries. The intensity of problems created by adhesion depends on factors such as density, location, tenacity and size. Anti-adhesion products help in reducing post-operative adhesions by forming a mechanical obstruction between organs and internal tissues. Substantial risk of contracting adhesions post surgery offers substantial case for driving the usage of adhesion prevention products in a significant number of surgeries over the following years. Adhesion-prevention products comprise various materials with different formulations for minimizing the irritation during their eventual resorbing on site.
The growth in the global anti-adhesion products market is an outcome of interplay of several factors, including demographics, number of surgical procedures being carried out, product awareness levels, and technological advancements, among others. Procedural count is a major factor determining the demand for adhesion prevention products. Given the fact that these products are used after a surgical procedure, there is direct correlation between these two variables. Awareness levels on benefits offered by these products are growing worldwide, which would immensely benefit volume growth of these products. Through time, these products have the potential of becoming routine in the surgical settings, given the wide array of benefits offered by their use in various surgeries. The surgical market is marked by conspicuous absence of suitable substitutes to adhesion prevention products with similar efficacy profiles. This has led to continued rise in adoption of these products. However, certain unmet needs exist in the market, which continues to inspire manufacturers to develop novel products and upgrade existing ones.
The wound care segment, particularly anti-adhesion products is primarily driven by introduction of new and improved products as well as technologies in tissue repair. Several companies are currently focused on development of effective anti-adhesion solutions that exhibit better clinical efficiency and expanded indications. Some of the new products in the market display the potential to reduce the complications associated with adhesions. Initially, most of the products were available as thin film barriers. These films, though effective had certain limitations in form of difficulty in handling and achievement of hemostasis before application. Some of these limitations have been overcome by innovative products in the form of gels, liquids, and more recently in spray forms. Following the approval of pipeline products, currently under clinical trials, the market is expected to report strong growth in the near term. Besides this, improving awareness and interest levels among surgeons is expected to catalyze existing competition.
Anti-adhesion products, alongside other wound care management products, have made substantial inroads into the area of surgical and traumatic wound management. Despite the substantial penetration, manufacturers continue to focus on development of novel adhesion prevention products in the market. Most new products are an extension to the existing options and improve substantially on early prototypes. Besides, the newly developed products focus on superior clinical efficacies when compared to existing options that warrant them to be offered at higher prices. However, these products are yet to reach their expectations on terms of revenues, and their revenue contribution is expected to only rise in the following years. Yet another factor that could wield a heavy influence on the market is the regulatory environment, which could foster growth or emerge as a limiting factor. In the present environment, significant pressures are on manufacturers to develop products that are not only more efficacious but also safer.
As stated by the new market research report on Anti-Adhesion Products, the US represents the largest regional market worldwide. Once the products receive approval, the US market becomes more appealing than any other market. One of the major factors determining this is the existence of more favorable trends in the US when compared to other regional markets, which culminate in higher adoption rates as well as higher market growth. However, Rest of World markets, comprising Canada, Asia-Pacific, Middle East and Africa, is projected to spearhead growth in the global market, with a CAGR of 9.8% during the analysis period. In terms of end-use segments, General/Abdominal Surgery represents the largest market for anti-adhesion products, while Pelvic/Gynecological Surgery is projected to spearhead growth in the market.
Simultaneous to the growing range of products, the anti-adhesion products market is also witnessing consolidation. Several leading companies have fortified their position in the market through technological partnerships or acquisition of venture-backed firms engaged in advanced research. Owing to low market acceptance and limited competition, price rise in the anti-adhesion products segment has been slow until recent years. Key players profiled in this report include Angiotech Pharmaceuticals Inc., Anika Therapeutics Inc., Ethicon, Inc., Genzyme Corporation, Covidien, FzioMed Inc., Integra LifeSciences Corporation, LifeCell Corporation and Pathfinder Cell Therapy, Inc., among others.
The research report titled Anti-Adhesion Products: A Global Strategic Business Report announced by Global Industry Analysts Inc., provides a comprehensive market overview, current market trends, key growth drivers, recent industry activity, and profiles of major/niche global market participants. The report provides annual sales estimates and projections for the years 2010 through 2018 in value terms (US$ ) for geographic markets including the US, Europe and Rest of World. Key end-use segments analyzed include General/Abdominal Surgery, Pelvic/Gynecological Surgery and Others (Cardiothoracic Surgery, ENT, and Spine/Neurology Surgery). The study also provides historic data for an insight into market evolution over the period 2004 through 2009.
For more details about this comprehensive market research report, please visit
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.
Follow us on LinkedIn
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/